hydroxyurea has been researched along with Astrocytoma, Grade IV in 36 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous daily schedule among recurrent malignant glioma patients." | 9.14 | Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. ( Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ, 2009) |
| "We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs)." | 9.14 | Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. ( Bergstrom, P; Blomquist, E; Campone, M; Clement, P; Dresemann, G; Easaw, J; Gijtenbeek, A; Gil, M; Gordower, L; Green, S; Hau, P; Nikolova, Z; Raizer, J; Reardon, DA; Schlegel, U; Schultz, H; Taillibert, S; Tonn, J; van den Bent, M; Weir, A, 2009) |
| "We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme (GBM)." | 9.11 | Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. ( Badruddoja, MA; Desjardins, A; Dowell, JM; Dresemann, G; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, I; Gururangan, S; Herndon, JE; Kicielinski, KP; Lagattuta, TF; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ, 2005) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 9.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "We investigated whether the hydroxyurea-induced loss of double-minute chromosomes containing amplified epidermal growth factor receptor (EGFR) genes would lead to a loss of tumorigenicity of a glioblastoma multiforme cell line." | 7.70 | The hydroxyurea-induced loss of double-minute chromosomes containing amplified epidermal growth factor receptor genes reduces the tumorigenicity and growth of human glioblastoma multiforme. ( Canute, GW; Coyle, TE; Hahn, PJ; Longo, JA; Longo, SL; Shetler, MM; Winfield, JA, 1998) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "We sought to determine whether hydroxyurea could accelerate the loss of amplified epidermal growth factor receptor (EGFR) genes from glioblastoma multiforme (GBM)." | 7.69 | Hydroxyurea accelerates the loss of epidermal growth factor receptor genes amplified as double-minute chromosomes in human glioblastoma multiforme. ( Canute, GW; Hahn, PJ; Longo, JA; Longo, SL; Nevaldine, BH; Winfield, JA, 1996) |
| "Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole." | 7.67 | 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 7.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| "This study determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous daily schedule among recurrent malignant glioma patients." | 5.14 | Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. ( Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ, 2009) |
| "We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs)." | 5.14 | Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. ( Bergstrom, P; Blomquist, E; Campone, M; Clement, P; Dresemann, G; Easaw, J; Gijtenbeek, A; Gil, M; Gordower, L; Green, S; Hau, P; Nikolova, Z; Raizer, J; Reardon, DA; Schlegel, U; Schultz, H; Taillibert, S; Tonn, J; van den Bent, M; Weir, A, 2009) |
| "We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme (GBM)." | 5.11 | Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. ( Badruddoja, MA; Desjardins, A; Dowell, JM; Dresemann, G; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, I; Gururangan, S; Herndon, JE; Kicielinski, KP; Lagattuta, TF; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ, 2005) |
| "In an attempt to improve the primary treatment of malignant gliomas we used a concomitant 6-week course of chemoradiotherapy with 5 fluorouracil (5 FU) and hydroxyurea (HU) in 24 adults with anaplastic astrocytoma (AA) (7 cases) or glioblastomas (GLB) (17 cases)." | 5.07 | Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. ( Armand, JP; Cioloca, C; Constans, JP; Cvitkovic, FB; Haie-Meder, C; Maugis, N; Papadimitrakopoulou, V, 1993) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 5.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "Imatinib mesylate is used in combination with hydroxyurea (HU) in ongoing clinical phase II studies in recurrent glioblastoma multiforme (GBM)." | 3.74 | Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ( Bornhäuser, M; Dresemann, G; Ehninger, G; Hosius, C; Illmer, T; Nikolova, Z; Prondzinsky, R; Pursche, S; Said, SM; Schleyer, E; von Bonin, M; Wang, Y, 2008) |
| "The combination of imatinib mesylate and hydroxyurea provides a therapeutic benefit in patients with glioblastoma, although each drug is not effective when used alone." | 3.73 | Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier. ( Bihorel, S; Camenisch, G; Gross, G; Lemaire, M; Scherrmann, JM, 2006) |
| " To elucidate the role of DNA synthesis inhibition in the cytotoxicity of dFdCyd, we compared dFdCyd to hydroxyurea (HU), a ribonucleotide reductase inhibitor, and aphidicolin, an inhibitor of DNA polymerases, in the U251 and D54 human glioblastoma cell lines." | 3.72 | The role of DNA synthesis inhibition in the cytotoxicity of 2',2'-difluoro-2'-deoxycytidine. ( Ostruszka, LJ; Shewach, DS, 2003) |
| "We investigated whether the hydroxyurea-induced loss of double-minute chromosomes containing amplified epidermal growth factor receptor (EGFR) genes would lead to a loss of tumorigenicity of a glioblastoma multiforme cell line." | 3.70 | The hydroxyurea-induced loss of double-minute chromosomes containing amplified epidermal growth factor receptor genes reduces the tumorigenicity and growth of human glioblastoma multiforme. ( Canute, GW; Coyle, TE; Hahn, PJ; Longo, JA; Longo, SL; Shetler, MM; Winfield, JA, 1998) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "We sought to determine whether hydroxyurea could accelerate the loss of amplified epidermal growth factor receptor (EGFR) genes from glioblastoma multiforme (GBM)." | 3.69 | Hydroxyurea accelerates the loss of epidermal growth factor receptor genes amplified as double-minute chromosomes in human glioblastoma multiforme. ( Canute, GW; Hahn, PJ; Longo, JA; Longo, SL; Nevaldine, BH; Winfield, JA, 1996) |
| "Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole." | 3.67 | 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 3.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| " Furthermore, the non-cytolytic and non-cytotoxic metronomic dosage of hydroxyurea and temozolomide had increased the DBM therapy outcome by strengthening anti-tumor capability." | 1.62 | A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness. ( Borghetto, V; Costanzo, E; Di Bella, G, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (27.78) | 18.7374 |
| 1990's | 10 (27.78) | 18.2507 |
| 2000's | 10 (27.78) | 29.6817 |
| 2010's | 5 (13.89) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Di Bella, G | 1 |
| Borghetto, V | 1 |
| Costanzo, E | 1 |
| Teng, J | 1 |
| Hejazi, S | 1 |
| Hiddingh, L | 1 |
| Carvalho, L | 1 |
| de Gooijer, MC | 1 |
| Wakimoto, H | 1 |
| Barazas, M | 1 |
| Tannous, M | 1 |
| Chi, AS | 1 |
| Noske, DP | 1 |
| Wesseling, P | 1 |
| Wurdinger, T | 1 |
| Batchelor, TT | 1 |
| Tannous, BA | 1 |
| Morin, P | 1 |
| Ferguson, D | 1 |
| LeBlanc, LM | 1 |
| Hébert, MJ | 1 |
| Paré, AF | 1 |
| Jean-François, J | 1 |
| Surette, ME | 1 |
| Touaibia, M | 1 |
| Cuperlovic-Culf, M | 1 |
| Denysenko, T | 1 |
| Gennero, L | 1 |
| Juenemann, C | 1 |
| Morra, I | 1 |
| Masperi, P | 1 |
| Ceroni, V | 1 |
| Pragliola, A | 1 |
| Ponzetto, A | 1 |
| Melcarne, A | 1 |
| Pursche, S | 1 |
| Schleyer, E | 2 |
| von Bonin, M | 1 |
| Ehninger, G | 1 |
| Said, SM | 1 |
| Prondzinsky, R | 1 |
| Illmer, T | 1 |
| Wang, Y | 1 |
| Hosius, C | 2 |
| Nikolova, Z | 3 |
| Bornhäuser, M | 1 |
| Dresemann, G | 6 |
| Galldiks, N | 1 |
| Ullrich, R | 1 |
| Schroeter, M | 1 |
| Fink, GR | 1 |
| Kracht, LW | 1 |
| Reardon, DA | 3 |
| Egorin, MJ | 2 |
| Desjardins, A | 2 |
| Vredenburgh, JJ | 2 |
| Beumer, JH | 1 |
| Lagattuta, TF | 2 |
| Gururangan, S | 2 |
| Herndon, JE | 2 |
| Salvado, AJ | 2 |
| Friedman, HS | 2 |
| Weller, M | 1 |
| Rosenthal, MA | 1 |
| Wedding, U | 1 |
| Wagner, W | 1 |
| Engel, E | 1 |
| Heinrich, B | 1 |
| Mayer-Steinacker, R | 1 |
| Karup-Hansen, A | 1 |
| Fluge, O | 1 |
| Nowak, A | 1 |
| Mehdorn, M | 1 |
| Krex, D | 1 |
| Olver, IN | 1 |
| Steinbach, JP | 1 |
| Sieder, C | 1 |
| Sorenson, G | 1 |
| Parker, R | 1 |
| Taillibert, S | 1 |
| Campone, M | 1 |
| van den Bent, M | 1 |
| Clement, P | 1 |
| Blomquist, E | 1 |
| Gordower, L | 1 |
| Schultz, H | 1 |
| Raizer, J | 1 |
| Hau, P | 1 |
| Easaw, J | 1 |
| Gil, M | 1 |
| Tonn, J | 1 |
| Gijtenbeek, A | 1 |
| Schlegel, U | 1 |
| Bergstrom, P | 1 |
| Green, S | 1 |
| Weir, A | 1 |
| Paulsson, J | 1 |
| Lindh, MB | 1 |
| Jarvius, M | 1 |
| Puputti, M | 1 |
| Nistér, M | 1 |
| Nupponen, NN | 1 |
| Paulus, W | 1 |
| Söderberg, O | 1 |
| von Deimling, A | 1 |
| Joensuu, H | 1 |
| Ostman, A | 1 |
| Hasselblatt, M | 1 |
| Ostruszka, LJ | 1 |
| Shewach, DS | 1 |
| Au, WY | 1 |
| Hung, KN | 1 |
| Loong, F | 1 |
| Ma, SK | 1 |
| Quinn, JA | 1 |
| Rich, JN | 2 |
| Gururangan, I | 1 |
| Sathornsumetee, S | 1 |
| Provenzale, JM | 1 |
| Dowell, JM | 1 |
| Badruddoja, MA | 1 |
| McLendon, RE | 1 |
| Kicielinski, KP | 1 |
| Sampson, JH | 1 |
| Friedman, AH | 1 |
| Bihorel, S | 1 |
| Camenisch, G | 1 |
| Gross, G | 1 |
| Lemaire, M | 1 |
| Scherrmann, JM | 1 |
| Shah, GD | 1 |
| Silver, JS | 1 |
| Rosenfeld, SS | 1 |
| Gavrilovic, IT | 1 |
| Abrey, LE | 1 |
| Lassman, AB | 1 |
| Levin, VA | 9 |
| Edwards, MS | 1 |
| Wara, WM | 6 |
| Allen, J | 1 |
| Ortega, J | 1 |
| Vestnys, P | 2 |
| Jeremic, B | 1 |
| Grujicic, D | 1 |
| Antunovic, V | 1 |
| Djuric, L | 1 |
| Stojanovic, M | 1 |
| Shibamoto, Y | 1 |
| Sneed, PK | 3 |
| Gutin, PH | 4 |
| Larson, DA | 3 |
| Malec, MK | 1 |
| Phillips, TL | 3 |
| Prados, MD | 4 |
| Scharfen, CO | 1 |
| Weaver, KA | 2 |
| Cvitkovic, FB | 1 |
| Haie-Meder, C | 1 |
| Papadimitrakopoulou, V | 1 |
| Armand, JP | 1 |
| Cioloca, C | 1 |
| Maugis, N | 1 |
| Constans, JP | 1 |
| Vokes, EE | 1 |
| Dolan, ME | 1 |
| Krishnasamy, S | 1 |
| Mick, R | 1 |
| Ratain, MJ | 1 |
| Berezin, F | 1 |
| Brachman, D | 1 |
| Whitman, G | 1 |
| Schilsky, RL | 1 |
| Charette, J | 1 |
| Kyritsis, AP | 1 |
| Yung, WK | 1 |
| Jaeckle, KA | 1 |
| Bruner, J | 1 |
| Gleason, MJ | 1 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Canute, GW | 2 |
| Longo, SL | 2 |
| Longo, JA | 2 |
| Winfield, JA | 2 |
| Nevaldine, BH | 1 |
| Hahn, PJ | 2 |
| Lamborn, K | 1 |
| McDermott, MW | 1 |
| Chang, SM | 1 |
| Mack, EE | 1 |
| Krouwer, HG | 1 |
| Chandler, KL | 1 |
| Warnick, RE | 1 |
| Davis, RL | 3 |
| Rabbitt, JE | 1 |
| Malec, M | 1 |
| Wilson, CB | 4 |
| Shetler, MM | 1 |
| Coyle, TE | 1 |
| Davis, R | 2 |
| Pischer, TL | 2 |
| Irwin, L | 2 |
| Wara, W | 1 |
| Costanza, M | 1 |
| Buechler, M | 1 |
| Munzenreider, J | 1 |
| Emami, B | 1 |
| Mukherji, B | 1 |
| Shucart, W | 1 |
| Scott, M | 1 |
| Nathanson, L | 1 |
| Rudders, R | 1 |
| Stein, B | 1 |
| Post, K | 1 |
| Piro, A | 1 |
| Resser, KJ | 1 |
| Yatsko, K | 1 |
| Nutik, S | 1 |
| Phuphanich, S | 1 |
| Liu, HC | 1 |
| Da Silva, V | 1 |
| Murovic, J | 1 |
| Choucair, A | 1 |
| Chamberlain, M | 1 |
| Berger, M | 1 |
| Seager, M | 1 |
| Pendergrass, TW | 1 |
| Milstein, JM | 1 |
| Geyer, JR | 1 |
| Mulne, AF | 1 |
| Kosnik, EJ | 1 |
| Morris, JD | 1 |
| Heideman, RL | 1 |
| Ruymann, FB | 1 |
| Stuntz, JT | 1 |
| Bleyer, WA | 1 |
| Broder, LE | 1 |
| Rall, DP | 1 |
| Yamada, S | 1 |
| Perot, PL | 1 |
| Ducker, TB | 1 |
| Gale, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea[NCT00387933] | Phase 1 | 37 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydroxyurea and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Chemotherapy of primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Brain Stem; Child; Efl | 1985 |
Chemotherapy of brain tumors.
Topics: Adult; Antineoplastic Agents; Azaguanine; Bleomycin; Brain Neoplasms; Child; Cyclophosphamide; Drug | 1972 |
14 trials available for hydroxyurea and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Gl | 2009 |
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brai | 2010 |
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Be | 2009 |
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Drug Resistance, Neopla | 2011 |
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms | 2005 |
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2005 |
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Bone Marrow Di | 2007 |
Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain; Brain Neoplasms; | 1994 |
Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1993 |
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Chemotherapy, Adjuvant; Dr | 1993 |
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cobalt Radioisotope | 1979 |
Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Glioblastoma; Glio | 1979 |
Radiation plus adjuvant CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) vs CCNU, hpydroxyurea and vincristine in the treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Bone Marrow; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combi | 1979 |
Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
20 other studies available for hydroxyurea and Astrocytoma, Grade IV
| Article | Year |
|---|---|
A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness.
Topics: Acetazolamide; Antioxidants; Brain Neoplasms; Ditiocarb; Glioblastoma; Humans; Hydroxyurea; Melatoni | 2021 |
Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; DNA Repl | 2018 |
NMR metabolomics analysis of the effects of 5-lipoxygenase inhibitors on metabolism in glioblastomas.
Topics: Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Caffeic Acids; Cell Line, Tumor; Drug Screening | 2013 |
Heterogeneous phenotype of human glioblastoma: in vitro study.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Di | 2014 |
Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Combined Modalit | 2009 |
The role of DNA synthesis inhibition in the cytotoxicity of 2',2'-difluoro-2'-deoxycytidine.
Topics: Antineoplastic Agents; Aphidicolin; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chromatography | 2003 |
Patients presenting with CNS lesions. Case 3. Sequential myeloproliferative disease and glioblastoma multiforme in a renal transplant recipient.
Topics: Administration, Oral; Brain Neoplasms; Chronic Disease; Diagnosis, Differential; Female; Frontal Lob | 2003 |
Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Benzamides; Biological Transport; Blood-Brain Barrier; Brain; Gliobl | 2006 |
5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bra | 1984 |
Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Ch | 1994 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
Hydroxyurea accelerates the loss of epidermal growth factor receptor genes amplified as double-minute chromosomes in human glioblastoma multiforme.
Topics: Aged; Animals; Blotting, Southern; Cell Division; Cells, Cultured; Chromosomes; Dose-Response Relati | 1996 |
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1998 |
The hydroxyurea-induced loss of double-minute chromosomes containing amplified epidermal growth factor receptor genes reduces the tumorigenicity and growth of human glioblastoma multiforme.
Topics: Animals; Carcinogenicity Tests; Cell Cycle; Cell Division; Chromosomes; ErbB Receptors; Female; Gene | 1998 |
Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle | 1992 |
Brachytherapy of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Child; Combined Moda | 1992 |
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1986 |
Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Cisplatin; Comb | 1987 |
Effect of prolonged continuous intracarotid arterial perfusion of hydroxyurea on the normal monkey brain.
Topics: Animals; Brain; Carotid Arteries; Glioblastoma; Haplorhini; Hydroxyurea; Hypoxia; Macaca; Methods; P | 1974 |